Literature DB >> 21745639

Ephrin-mediated cis-attenuation of Eph receptor signaling is essential for spinal motor axon guidance.

Tzu-Jen Kao1, Artur Kania.   

Abstract

Axon guidance receptors guide neuronal growth cones by binding in trans to axon guidance ligands in the developing nervous system. Some ligands are coexpressed in cis with their receptors, raising the question of the relative contribution of cis and trans interactions to axon guidance. Spinal motor axons use Eph receptors to select a limb trajectory in response to trans ephrins, while expressing ephrins in cis. We show that changes in motor neuron ephrin expression result in trajectory selection defects mirrored by changes in growth cone sensitivity to ephrins in vitro, arguing for ephrin cis-attenuation of Eph function. Furthermore, the relative contribution of trans-signaling and cis-attenuation is influenced by the subcellular distribution of ephrins to membrane patches containing Eph receptors. Thus, growth cone ephrins are essential for axon guidance in vivo and the balance between cis and trans modes of axon guidance ligand-receptor interaction contributes to the diversity of axon guidance signaling responses.
Copyright © 2011 Elsevier Inc. All rights reserved.

Mesh:

Substances:

Year:  2011        PMID: 21745639     DOI: 10.1016/j.neuron.2011.05.031

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  56 in total

Review 1.  Mechanisms of ephrin-Eph signalling in development, physiology and disease.

Authors:  Artur Kania; Rüdiger Klein
Journal:  Nat Rev Mol Cell Biol       Date:  2016-01-21       Impact factor: 94.444

2.  Concentration-dependent requirement for local protein synthesis in motor neuron subtype-specific response to axon guidance cues.

Authors:  Stéphane Nédelec; Mirza Peljto; Peng Shi; Mackenzie W Amoroso; Lance C Kam; Hynek Wichterle
Journal:  J Neurosci       Date:  2012-01-25       Impact factor: 6.167

Review 3.  Regulation and misregulation of Eph/ephrin expression.

Authors:  Dina N Arvanitis; Alice Davy
Journal:  Cell Adh Migr       Date:  2012-03-01       Impact factor: 3.405

Review 4.  Therapeutic targeting of EPH receptors and their ligands.

Authors:  Andrew W Boyd; Perry F Bartlett; Martin Lackmann
Journal:  Nat Rev Drug Discov       Date:  2014-01       Impact factor: 84.694

Review 5.  Transcriptional regulation of guidance at the midline and in motor circuits.

Authors:  Aref Arzan Zarin; Jamshid Asadzadeh; Juan-Pablo Labrador
Journal:  Cell Mol Life Sci       Date:  2013-08-06       Impact factor: 9.261

6.  Insights into Eph receptor tyrosine kinase activation from crystal structures of the EphA4 ectodomain and its complex with ephrin-A5.

Authors:  Kai Xu; Dorothea Tzvetkova-Robev; Yan Xu; Yehuda Goldgur; Yee-Peng Chan; Juha P Himanen; Dimitar B Nikolov
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-19       Impact factor: 11.205

Review 7.  Eph receptor signaling and ephrins.

Authors:  Erika M Lisabeth; Giulia Falivelli; Elena B Pasquale
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-09-01       Impact factor: 10.005

8.  Ephrin-A5/EphA4 signalling controls specific afferent targeting to cochlear hair cells.

Authors:  Jean Defourny; Anne-Lise Poirrier; François Lallemend; Susana Mateo Sánchez; Jakob Neef; Pierre Vanderhaeghen; Eduardo Soriano; Christiane Peuckert; Klas Kullander; Bernd Fritzsch; Laurent Nguyen; Gustave Moonen; Tobias Moser; Brigitte Malgrange
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

9.  Developmental Regulation of Basket Interneuron Synapses and Behavior through NCAM in Mouse Prefrontal Cortex.

Authors:  Chelsea S Sullivan; Vishwa Mohan; Paul B Manis; Sheryl S Moy; Young Truong; Bryce W Duncan; Patricia F Maness
Journal:  Cereb Cortex       Date:  2020-06-30       Impact factor: 5.357

Review 10.  Eph receptor tyrosine kinases in cancer stem cells.

Authors:  Jin Chen; Wenqiang Song; Katherine Amato
Journal:  Cytokine Growth Factor Rev       Date:  2014-05-17       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.